A Randomized, Double Blind, Placebo-Controlled, Phase IIIb Study of the Efficacy and Safety of Continuing Enzalutamide in Chemotherapy Naive Metastatic Castration Resistant Prostate Cancer Patients Treated With Docetaxel Plus Prednisolone Who Have Progressed on Enzalutamide Alone
Active, no longer recruiting
Phase of Trial: Phase III
Latest Information Update: 07 Jul 2017
At a glance
- Drugs Enzalutamide (Primary) ; Docetaxel; Prednisolone
- Indications Adenocarcinoma; Prostate cancer
- Focus Registrational; Therapeutic Use
- Acronyms PRESIDE
- Sponsors Astellas Pharma Europe Ltd
- 30 Jun 2017 Planned End Date changed from 30 Nov 2018 to 1 Oct 2018.
- 30 Jun 2017 Planned primary completion date changed from 30 Nov 2018 to 1 Oct 2018.
- 10 Jun 2017 Biomarkers information updated